Rhiannon McNeill

Dr. Rhiannon McNeill

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2023 in Neuroscience Applied
Verified
Journal Article
Open access
LPLucia Dutan Polit
Lucia Dutan Polit
IEIlse Eidhof
Ilse Eidhof
RMRhiannon McNeill
Rhiannon McNeill
KWKatherine M. Warre-Cornish
Katherine M. Warre-Cornish
COCristine Marie Yde Ohki
Cristine Marie Yde Ohki
DSDeepak P. Srivastava
Deepak P. Srivastava
The number of individuals suffering from neuropsychiatric disorders (NPDs) has increased worldwide, with 3 million disability-adjusted life-years calculated in 2019. Though research using various approaches including genetics, imaging, clinical and animal models has advanced our knowledge regarding NPDs, we still lack basic knowledge regarding the underlying pathophysiological mechanisms. Moreover, there is an urgent need for highly effective therapeutics for NPDs. Human induced pluripotent stem cells (hiPSCs) generated from somatic cells enabled scientists to create brain cells in a patient-specific manner. However, there are challenges to the use of hiPSCs that need to be addressed. In the current paper, consideration of best practices for neuropharmacological and neuropsychiatric research using hiPSCs will be discussed. Specifically, we provide recommendations for best practice in patient recruitment, including collecting demographic, clinical, medical (before and after treatment and response), diagnostic (including scales) and genetic data from the donors. We highlight considerations regarding donor genetics and sex, in addition to discussing biological and technical replicates. Furthermore, we present our views on selecting control groups/lines, experimental designs, and considerations for conducting neuropharmacological studies using hiPSC-based models in the context of NPDs. In doing so, we explore key issues in the field concerning reproducibility, statistical analysis, and how to translate in vitro studies into clinically relevant observations. The aim of this article is to provide a key resource for hiPSC researchers to perform robust and reproducible neuropharmacological studies, with the ultimate aim of improving identification and clinical translation of novel therapeutic drugs for NPDs.

8 October 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SKSarah Kittel-Schneider
Sarah Kittel-Schneider
SWSarah Wolff
Sarah Wolff
KQKristin Queiser
Kristin Queiser
LWLeonie Wessendorf
Leonie Wessendorf
AMAnna Maria Meier
Anna Maria Meier
ARAndreas Reif
Andreas Reif
Background: Recent research has shown an increased risk of accidents and injuries in ADHD patients, which could potentially be reduced by stimulant treatment. Therefore, the first aim of our study was to evaluate the prevalence of adult ADHD in a trauma surgery population. The second aim was to investigate accident mechanisms and circumstances which could be specific to ADHD patients, in comparison to the general population. Methods: We screened 905 accident victims for ADHD using the ASRS 18-item self-report questionnaire. The basic demographic data and circumstances of the accidents were also assessed. Results: Prevalence of adult ADHD was found to be 6.18% in our trauma surgery patient sample. ADHD accident victims reported significantly higher rates of distraction, stress and overconfidence in comparison to non-ADHD accident victims. Overconfidence and being in thoughts as causal mechanisms for the accidents remained significantly higher in ADHD patients after correction for multiple comparison. ADHD patients additionally reported a history of multiple accidents. Conclusion: The majority of ADHD patients in our sample had not previously been diagnosed and were therefore not receiving treatment. The results subsequently suggest that general ADHD screening in trauma surgery patients may be useful in preventing further accidents in ADHD patients. Furthermore, psychoeducation regarding specific causal accident mechanisms could be implemented in ADHD therapy to decrease accident incidence rate.

18 December 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VPViola Stella Palladino
Viola Stella Palladino
Andreas G. ChiocchettiAndreas G. Chiocchetti
Andreas G. Chiocchetti
LFLukas Frank
Lukas Frank
DHDenise Haslinger
Denise Haslinger
RMRhiannon McNeill
Rhiannon McNeill
SKSarah Kittel-Schneider
Sarah Kittel-Schneider
The main goal of the present study was the identification of cellular phenotypes in attention-deficit-/hyperactivity disorder (ADHD) patient-derived cellular models from carriers of rare copy number variants (CNVs) in the PARK2 locus that have been previously associated with ADHD. Human-derived fibroblasts (HDF) were cultured and human-induced pluripotent stem cells (hiPSC) were reprogrammed and differentiated into dopaminergic neuronal cells (mDANs). A series of assays in baseline condition and in different stress paradigms (nutrient deprivation, carbonyl cyanide m-chlorophenyl hydrazine (CCCP)) focusing on mitochondrial function and energy metabolism (ATP production, basal oxygen consumption rates, reactive oxygen species (ROS) abundance) were performed and changes in mitochondrial network morphology evaluated. We found changes in PARK2 CNV deletion and duplication carriers with ADHD in PARK2 gene and protein expression, ATP production and basal oxygen consumption rates compared to healthy and ADHD wildtype control cell lines, partly differing between HDF and mDANs and to some extent enhanced in stress paradigms. The generation of ROS was not influenced by the genotype. Our preliminary work suggests an energy impairment in HDF and mDAN cells of PARK2 CNV deletion and duplication carriers with ADHD. The energy impairment could be associated with the role of PARK2 dysregulation in mitochondrial dynamics.

15 January 2022 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
RMRhiannon McNeill
Rhiannon McNeill
CKChristopher Kehrwald
Christopher Kehrwald
MBMurielle Brum
Murielle Brum
KKKatrin Knopf
Katrin Knopf
NBNathalie Brunkhorst-Kanaan
Nathalie Brunkhorst-Kanaan
SKSarah Kittel-Schneider
Sarah Kittel-Schneider

4 September 2020 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
RMRhiannon McNeill
Rhiannon McNeill
VPViola Stella Palladino
Viola Stella Palladino
NBNathalie Brunkhorst-Kanaan
Nathalie Brunkhorst-Kanaan
OGOliver Grimm
Oliver Grimm
ARAndreas Reif
Andreas Reif
SKSarah Kittel-Schneider
Sarah Kittel-Schneider
Objectives: ADGRL3 is a well-replicated risk genes for adult ADHD, encoding the G-protein coupled receptor latrophilin-3 (LPHN3). However, LPHN3’s potential role in pathogenesis is unclear. We aimed to determine whether ADGRL3 expression could be dysregulated by genetic risk variants and/or ADHD-associated environmental risk factors. Methods: 18 adult ADHD patients and healthy controls were genotyped for rs734644, rs1397547, rs1397548, rs2271338, rs2305339, rs2345039 and rs6551665 ADGRL3 SNPs, and fibroblast cells were derived from skin punches. The environmental ADHD risk factors ‘low birthweight’ and ‘maternal smoking’ were modelled in fibroblast cell culture using starvation and nicotine exposure, respectively. Quantitative real-time PCR and Western blotting were performed to quantify ADGRL3 gene and protein expression under control, starvation and nicotine-exposed conditions. Results: Starvation was found to significantly decrease ADGRL3 expression, whereas nicotine exposure significantly increased ADGRL3 expression. rs1397547 significantly elevated ADGRL3 transcription and protein expression. rs6551665 and rs2345039 interacted with environment to modulate ADGRL3 transcription. ADGRL3 SNPs were significantly able to predict its transcription under both baseline and starvation conditions, and rs1397547 was identified as a significant independent predictor. Conclusions: ADGRL3 SNPs and environmental risk factors can regulate ADGRL3 expression, providing a potential functional mechanism by which LPHN3 may play a role in ADHD pathogenesis.

5 January 2023 in Stem Cell Research
Verified
Journal Article
Open access
RMRhiannon McNeill
Rhiannon McNeill
FRFranziska Radtke
Franziska Radtke
MNMatthias Nieberler
Matthias Nieberler
CKCarolin Koreny
Carolin Koreny
ACAndreas G. Chiocchetti
Andreas G. Chiocchetti
SKSarah Kittel-Schneider
Sarah Kittel-Schneider
Single nucleotide polymorphisms (SNPs) in the ADGRL3 gene have been significantly associated with the development of ADHD, the aetiology of which remains poorly understood. The rs1397547 SNP has additionally been associated with significantly altered ADGRL3 transcription. We therefore generated iPSCs from two wild type ADHD patients, and two ADHD patients heterozygous for the risk SNP. With this resource we aim to facilitate further investigation into the complex and heterogenous pathology of ADHD. Furthermore, we demonstrate the feasibility of using magnetic activated cell sorting to allow the unbiased selection of fully reprogrammed iPSCs.